---
figid: PMC7024330__molecules-25-00358-g002
figlink: pmc/articles/PMC7024330/figure/molecules-25-00358-f002/
number: F2
caption: 'AR signaling pathway and targeted therapeutic strategies against AR. AR
  can regulate the proliferation, migration, and invasiveness in BC through genomic
  and/or nongenomic pathways. CYP17A1 is the enzyme that converts androgen precursors
  into DHEA, HSD3β1 catalyzes DHEA to AD, while AKR1C3 converts AD to testosterone;
  finally, testosterone is catalyzed to DHT by 5α-reductase. In the genomic way of
  AR activation, DHT binds and activates AR, which disassociates from heat shock proteins
  and forms dimers, which translocate to the nucleus, where gene transcription is
  modulated by binding to the androgen response elements of target genes. In the nongenomic
  way of AR activation, ERK-mediated AR signaling involves phosphoinositide 3-kinase
  (PI3K), Src proteins, and Ras GTPase. Abiraterone acetate selectively and irreversibly
  blocks CYP17A1 activity. Drugs: Seviteronel is a CYP17A1 inhibitor. Bicalutamide
  is a first-generation and Enzalutamide a second-generation AR antagonist that blocks
  androgens binding to AR. Enzalutamide also inhibits AR nuclear translocation and
  AR-mediated transcription. In the nongenomic way of AR activation, the use of AR
  antagonists/inhibitors of AR-activated proteins that disrupts the AR/src association
  could be a starting point to reduce BC cell proliferation. Abbreviations: AD—androstenedione;
  AKR1C3—aldo-keto reductase family 1 member C3; AP—androgen precursors; AR—androgen
  receptor; ARE—androgen receptor element; CYP17A1—cytochrome P450 c17; DHEA—dehydroepiandrosterone;
  DHT—dihydrotestosterone; HSP—heat shock protein; HSD3β1—human 3-beta-hydroxysteroid
  dehydroxynase/delta5-4 isomerase type 1; T—testosterone; TF—transcription factor.'
pmcid: PMC7024330
papertitle: Androgen Receptor in Breast Cancer—Clinical and Preclinical Research Insights.
reftext: Aristomenis Anestis, et al. Molecules. 2020 Jan;25(2):358.
pmc_ranked_result_index: '53563'
pathway_score: 0.9626089
filename: molecules-25-00358-g002.jpg
figtitle: AR signaling pathway and targeted therapeutic strategies against AR
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7024330__molecules-25-00358-g002.html
  '@type': Dataset
  description: 'AR signaling pathway and targeted therapeutic strategies against AR.
    AR can regulate the proliferation, migration, and invasiveness in BC through genomic
    and/or nongenomic pathways. CYP17A1 is the enzyme that converts androgen precursors
    into DHEA, HSD3β1 catalyzes DHEA to AD, while AKR1C3 converts AD to testosterone;
    finally, testosterone is catalyzed to DHT by 5α-reductase. In the genomic way
    of AR activation, DHT binds and activates AR, which disassociates from heat shock
    proteins and forms dimers, which translocate to the nucleus, where gene transcription
    is modulated by binding to the androgen response elements of target genes. In
    the nongenomic way of AR activation, ERK-mediated AR signaling involves phosphoinositide
    3-kinase (PI3K), Src proteins, and Ras GTPase. Abiraterone acetate selectively
    and irreversibly blocks CYP17A1 activity. Drugs: Seviteronel is a CYP17A1 inhibitor.
    Bicalutamide is a first-generation and Enzalutamide a second-generation AR antagonist
    that blocks androgens binding to AR. Enzalutamide also inhibits AR nuclear translocation
    and AR-mediated transcription. In the nongenomic way of AR activation, the use
    of AR antagonists/inhibitors of AR-activated proteins that disrupts the AR/src
    association could be a starting point to reduce BC cell proliferation. Abbreviations:
    AD—androstenedione; AKR1C3—aldo-keto reductase family 1 member C3; AP—androgen
    precursors; AR—androgen receptor; ARE—androgen receptor element; CYP17A1—cytochrome
    P450 c17; DHEA—dehydroepiandrosterone; DHT—dihydrotestosterone; HSP—heat shock
    protein; HSD3β1—human 3-beta-hydroxysteroid dehydroxynase/delta5-4 isomerase type
    1; T—testosterone; TF—transcription factor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKR1C3
  - HSD3B1
  - CYP17A1
  - AR
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - SRC
  - AKT2
  - AKT3
  - AKT1
  - MAPK3
  - MAPK1
  - MAPK14
  - MAPK8
  - MAPK11
  - MAPK13
  - MAPK12
  - MAPK9
  - MAPK10
  - JTB
  - TF
  - DHEA
  - Abiraterone
  - Enzalutamide
genes:
- word: AKR1C3
  symbol: AKR1C3
  source: hgnc_symbol
  hgnc_symbol: AKR1C3
  entrez: '8644'
- word: HSD3B1
  symbol: HSD3B1
  source: hgnc_symbol
  hgnc_symbol: HSD3B1
  entrez: '3283'
- word: CYP17A1
  symbol: CYP17A1
  source: hgnc_symbol
  hgnc_symbol: CYP17A1
  entrez: '1586'
- word: AR
  symbol: AR
  source: hgnc_symbol
  hgnc_symbol: AR
  entrez: '367'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: Src
  symbol: SRC
  source: hgnc_symbol
  hgnc_symbol: SRC
  entrez: '6714'
- word: AR
  symbol: AR
  source: hgnc_symbol
  hgnc_symbol: AR
  entrez: '367'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AR
  symbol: AR
  source: hgnc_symbol
  hgnc_symbol: AR
  entrez: '367'
- word: AR
  symbol: AR
  source: hgnc_symbol
  hgnc_symbol: AR
  entrez: '367'
- word: Src
  symbol: SRC
  source: hgnc_symbol
  hgnc_symbol: SRC
  entrez: '6714'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAPK/ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MAPK/ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAPK/ERK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: MAPK/ERK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MAPK/ERK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: MAPK/ERK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: MAPK/ERK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: MAPK/ERK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: MAPK/ERK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAPK/ERK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: MAPK/ERK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: PAR
  symbol: PAR
  source: hgnc_alias_symbol
  hgnc_symbol: JTB
  entrez: '10899'
- word: AR
  symbol: AR
  source: hgnc_symbol
  hgnc_symbol: AR
  entrez: '367'
- word: AR
  symbol: AR
  source: hgnc_symbol
  hgnc_symbol: AR
  entrez: '367'
- word: AR
  symbol: AR
  source: hgnc_symbol
  hgnc_symbol: AR
  entrez: '367'
- word: AR
  symbol: AR
  source: hgnc_symbol
  hgnc_symbol: AR
  entrez: '367'
- word: TF
  symbol: TF
  source: hgnc_symbol
  hgnc_symbol: TF
  entrez: '7018'
chemicals:
- word: DHEA
  source: MESH
  identifier: D003687
- word: Abiraterone
  source: MESH
  identifier: C089740
- word: Enzalutamide
  source: MESH
  identifier: C540278
diseases: []
figid_alias: PMC7024330__F2
redirect_from: /figures/PMC7024330__F2
figtype: Figure
---
